Latest Period
Q4 2025
Security Snapshot
Altimmune, Inc. - COMMON STOCK (ALT) Institutional Ownership
CUSIP: 02155H200
13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026
Institutions Reporting
182
Shares (Excl. Options)
54,848,617
Price
$3.61
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- ALT on Nasdaq
- Shares outstanding
- 129,919,091
- Price per share
- $3.38
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 54,848,617
- Total reported value
- $198,060,728
- % of total 13F portfolios
- 0%
- Share change
- +13,154,292
- Value change
- +$47,375,320
- Number of holders
- 182
- Price from insider filings
- $3.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ALT - Altimmune, Inc. - COMMON STOCK is tracked under CUSIP 02155H200.
- 182 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 182 to 77 between Q4 2025 and Q1 2026.
- Reported value moved from $198,060,728 to $63,462,747.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 182 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 02155H200?
CUSIP 02155H200 identifies ALT - Altimmune, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02155H200:
Significant Owners of Altimmune, Inc. - COMMON STOCK (ALT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 9.8% | $67,600,000 | 20,000,000 | Chen Yu | 24 Apr 2026 | |||
| Deep Track Capital, LP | 10% | $59,805,041 | 19,417,221 | Deep Track Capital, LP | 23 Apr 2026 | |||
| VIKING GLOBAL INVESTORS LP | 6.7% | $45,292,000 | 13,400,000 | VIKING GLOBAL INVESTORS LP | 24 Apr 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 6.5% | $43,940,000 | 13,000,000 | RA Capital Management, L.P. | 24 Apr 2026 | |||
| STATE STREET CORP | 5.5% | $24,151,959 | 7,145,550 | STATE STREET CORPORATION | 31 Mar 2026 | |||
| BlackRock, Inc. | 7.6% | -12% | $23,736,362 | -$100,148 | 6,133,427 | -0.42% | BlackRock, Inc. | 30 Jun 2025 |
| AMERIPRISE FINANCIAL INC | 1.9% | -79% | $7,306,296 | -$19,283,488 | 1,443,932 | -73% | Ameriprise Financial, Inc. | 31 Mar 2025 |
As of 31 Dec 2025, 182 institutional investors reported holding 54,848,617 shares of Altimmune, Inc. - COMMON STOCK (ALT). This represents 42% of the company’s total 129,919,091 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Altimmune, Inc. - COMMON STOCK (ALT) together control 36% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.5% | 9,704,298 | +52% | 0% | $35,032,515 |
| VANGUARD GROUP INC | 7.3% | 9,491,159 | +49% | 0% | $34,263,084 |
| STATE STREET CORP | 3.9% | 5,119,703 | +42% | 0% | $18,482,128 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 2,292,410 | +14% | 0% | $8,277,782 |
| TANG CAPITAL MANAGEMENT LLC | 1.6% | 2,131,307 | 0% | 0.38% | $7,694,018 |
| JANE STREET GROUP, LLC | 1.4% | 1,783,950 | +537% | 0.01% | $6,440,060 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.1% | 1,369,017 | -0.38% | 0.01% | $4,942,151 |
| MORGAN STANLEY | 1% | 1,359,885 | -8.8% | 0% | $4,909,186 |
| GOLDMAN SACHS GROUP INC | 1% | 1,349,293 | +140% | 0% | $4,870,948 |
| D. E. Shaw & Co., Inc. | 1% | 1,343,583 | +273% | 0% | $4,850,335 |
| CITADEL ADVISORS LLC | 1% | 1,337,927 | +4.4% | 0% | $4,829,917 |
| TWO SIGMA INVESTMENTS, LP | 0.97% | 1,265,683 | -37% | 0.01% | $4,569,116 |
| Nuveen, LLC | 0.96% | 1,244,211 | +515% | 0% | $4,491,602 |
| Knoll Capital Management, LLC | 0.86% | 1,121,524 | 0% | 1.9% | $4,048,701 |
| MARSHALL WACE, LLP | 0.71% | 922,777 | 0% | $3,331,226 | |
| TWO SIGMA ADVISERS, LP | 0.61% | 793,900 | -44% | 0.01% | $2,865,979 |
| NORTHERN TRUST CORP | 0.55% | 715,991 | +9% | 0% | $2,584,727 |
| UBS Group AG | 0.49% | 642,048 | -0.12% | 0% | $2,317,793 |
| FMR LLC | 0.43% | 564,093 | +27% | 0% | $2,036,376 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0.36% | 469,013 | 0% | $1,693,137 | |
| BARCLAYS PLC | 0.31% | 400,595 | +18% | 0% | $1,446,149 |
| Soviero Asset Management, LP | 0.31% | 400,000 | 0.75% | $1,444,000 | |
| BANK OF AMERICA CORP /DE/ | 0.3% | 383,783 | +20% | 0% | $1,385,456 |
| Beirne Wealth Consulting Services, LLC | 0.29% | 376,458 | -8.3% | 0.39% | $1,359,014 |
| Bank of New York Mellon Corp | 0.27% | 354,201 | +3.6% | 0% | $1,278,666 |
Institutional Holders of Altimmune, Inc. - COMMON STOCK (ALT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 20,604,597 | $63,462,747 | +$197,085 | $3.08 | 77 |
| 2025 Q4 | 54,848,617 | $198,060,728 | +$47,375,320 | $3.61 | 182 |
| 2025 Q3 | 41,476,255 | $156,373,200 | +$14,303,174 | $3.77 | 157 |
| 2025 Q2 | 37,594,851 | $145,435,659 | -$6,199,092 | $3.87 | 179 |
| 2025 Q1 | 38,134,819 | $190,969,777 | -$15,358,703 | $5.00 | 173 |
| 2024 Q4 | 40,453,394 | $291,649,491 | +$7,414,850 | $7.21 | 180 |
| 2024 Q3 | 39,490,913 | $242,642,286 | -$19,754,298 | $6.14 | 167 |
| 2024 Q2 | 42,376,353 | $281,796,522 | -$21,723,923 | $6.65 | 173 |
| 2024 Q1 | 44,351,359 | $451,471,154 | +$108,533,821 | $10.18 | 166 |
| 2023 Q4 | 33,518,969 | $377,122,817 | +$87,837,677 | $11.25 | 142 |
| 2023 Q3 | 30,119,653 | $78,312,976 | -$14,266,982 | $2.60 | 110 |
| 2023 Q2 | 35,266,907 | $124,503,782 | -$30,995,734 | $3.53 | 118 |
| 2023 Q1 | 40,146,839 | $169,418,214 | -$115,027,226 | $4.22 | 129 |
| 2022 Q4 | 46,782,400 | $769,520,216 | +$29,466,534 | $16.45 | 122 |
| 2022 Q3 | 46,027,433 | $587,716,469 | +$80,574,668 | $12.77 | 116 |
| 2022 Q2 | 39,903,915 | $466,872,641 | +$78,793,572 | $11.70 | 102 |
| 2022 Q1 | 33,651,643 | $207,371,526 | +$5,868,022 | $6.09 | 96 |
| 2021 Q4 | 32,470,413 | $295,787,573 | -$27,220,088 | $9.16 | 98 |
| 2021 Q3 | 32,076,209 | $363,055,937 | +$59,058,531 | $11.31 | 113 |
| 2021 Q2 | 27,191,172 | $267,846,675 | +$16,710,421 | $9.85 | 102 |
| 2021 Q1 | 23,819,490 | $336,535,131 | +$49,552,065 | $14.13 | 92 |
| 2020 Q4 | 20,471,521 | $230,916,860 | -$28,712,052 | $11.28 | 83 |
| 2020 Q3 | 21,898,188 | $289,049,000 | +$115,723,197 | $13.20 | 67 |
| 2020 Q2 | 13,311,955 | $142,567,171 | +$125,471,540 | $10.71 | 53 |
| 2020 Q1 | 1,583,373 | $5,082,210 | +$1,206,160 | $3.21 | 20 |
| 2019 Q4 | 1,281,842 | $2,423,890 | +$314,812 | $1.89 | 21 |
| 2019 Q3 | 1,113,862 | $2,171,952 | +$159,903 | $1.95 | 22 |
| 2019 Q2 | 1,032,457 | $2,456,382 | -$456,118 | $2.37 | 15 |
| 2019 Q1 | 1,114,198 | $3,229,903 | +$1,231,709 | $2.90 | 13 |
| 2018 Q4 | 806,802 | $1,663,208 | +$928,520 | $2.06 | 16 |
| 2018 Q3 | 193,862 | $853,444 | +$853,440 | $4.40 | 7 |